DOCSLIB.ORG

Key Roles for MED1 Lxxll Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Key Roles for MED1 Lxxll Motifs in Pubertal Mammary Gland Development and Luminal-Cell Differentiation Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation Pingping Jianga,b,1, Qiuping Hua,1, Mitsuhiro Itoc,1,3, Sara Meyera, Susan Waltza, Sohaib Khana, Robert G. Roederc,2, and Xiaoting Zhanga,2 aDepartment of Cancer and Cell Biology, College of Medicine, University of Cincinnati, 3125 Eden Avenue, OH 45267; bCollege of Life Sciences, Zhejiang University, 388 Yuhangtang Road, Hangzhou 310058, China; and cLaboratory of Biochemistry and Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065 Contributed by Robert G. Roeder, February 16, 2010 (sent for review January 18, 2010) Mediator recently has emerged as a central player in the direct (7–9). In general, individual Mediator subunits interact transduction of signals from transcription factors to the general specifically with their corresponding transcription factors and de- transcriptional machinery. In the case of nuclear receptors, in vitro letions of these Mediator subunits often affect expression primar- studies have shown that the transcriptional coactivator function of ily of target genes and pathways controlled by their corresponding the Mediator involves direct ligand-dependent interactions of the transcription factor(s) (9). In the case of nuclear receptors, the MED1 subunit, through its two classical LxxLL motifs, with the re- Mediator interactions are ligand- and AF-2-dependent and ceptor AF2 domain. However, despite the strong in vitro evidence, mediated through the LxxLL motifs in the MED1 (a.k.a. there currently is little information regarding in vivo functions of TRAP220/PBP/DRIP205) subunit (10–13). Importantly, in rela- the LxxLL motifs either in MED1 or in other coactivators. Toward tion to the present study, in vitro assays with intact Mediator com- this end, we have generated MED1 LxxLL motif-mutant knockin plexes containing mutated MED1 LxxLL motifs have established mice. Interestingly, these mice are both viable and fertile and do direct roles for the LxxLL motifs in strong (ligand-dependent) not exhibit any apparent gross abnormalities. However, they do nuclear receptor-Mediator interactions and in Mediator-depen- BIOCHEMISTRY exhibit severe defects in pubertal mammary gland development. dent transcription by nuclear receptors (14, 15). Consistent with this phenotype, as well as loss of the strong li- LxxLL motifs were initially discovered in SRC1 and CREB- gand-dependent estrogen receptor (ER)α-Mediator interaction, ex- binding protein/p300 (16) and later reported in many other pression of a number of known ERα-regulated genes was down- nuclear receptor coactivators including MED1 and SRC/p160 regulated in MED1-mutant mammary epithelial cells and could and PGC-1 family members (4, 17). Crystal structures of the no longer respond to estrogen stimulation. Related, estrogen-sti- agonist-bound nuclear receptor AF-2 domains with LxxLL motifs mulated mammary duct growth in MED1-mutant mice was also have provided considerable mechanistic insights into their inter- greatly diminished. Finally, additional studies show that MED1 is actions (17–20). Although the LxxLL motif itself is sufficient to differentially expressed in different types of mammary epithelial mediate nuclear receptor interactions, sequences flanking the cells and that its LxxLL motifs play a role in mammary luminal LxxLL motifs play key roles in determining receptor binding epithelial cell differentiation and progenitor/stem cell determina- specificity (19, 20) and allow division of LxxLL motifs into several tion. Our results establish a key nuclear receptor- and cell-specific classes according to their flanking sequences (reviewed in ref. 17). in vivo role for MED1 LxxLL motifs, through Mediator-ERα interac- The fact that diverse coactivators such as SRC/p160, MED1, and tions, in mammary gland development. PGC-1 have overlapping interaction sites on the AF-2 domain has led to the concept of cofactor exchange during transcriptional MED1/TRAP220 ∣ estrogen receptor ∣ progenitor/stem cell activation (4, 21). Interestingly, and related, recent studies have identified AF-2 domain mutations that result either in selective uclear receptors are a family of transcription factors that, in loss of TRβ binding to SRC/p160 relative to PGC-1α (22) or in Nresponse to small lipophilic ligands, specifically regulate selective loss of ERα binding to SRC/p160 family members rela- expression of target genes in development, differentiation, meta- tive to MED1 (23). These findings have led to the idea that these bolism, homeostasis, and reproduction (1, 2). These nuclear motifs could be targets for the development of reagents that se- receptors are expressed in a developmental stage- and tissue- lectively disrupt nuclear receptor interactions with certain coac- specific manner and play important roles, not only in normal phy- tivator complexes to achieve tissue- and gene-specific therapeutic siology, but also in pathological conditions (1, 2). Nuclear recep- interventions (6). tors have characteristic domains that include an N-terminal AF-1 Although it has been shown that the LxxLL motifs of MED1 domain that mediates ligand-independent transcription, a central are required for its interactions with nuclear receptors and for DNA-binding domain that binds to regulatory elements in cog- nuclear receptor-mediated transcription in vitro, there is no avail- nate target genes, and a C-terminal ligand-binding domain with able information regarding the functional significance of MED1 an associated (ligand-induced) AF-2 domain that mediates ligand-dependent activation of target genes (1, 2). Author contributions: P.J., Q.H., M.I., R.G.R., and X.Z. designed research; P.J., Q.H., S.M., The ultimate action of nuclear receptors following binding to M.I., and X.Z. performed research; P.J., Q.H., S.W., S.K., M.I., R.G.R., and X.Z. analyzed data; target genes is to enhance the recruitment and/or function of the and R.G.R. and X.Z. wrote the paper. general transcription machinery, including RNA polymerase II The authors declare no conflict of interest. and general transcription factors, on cognate core promoter 1P.J., Q.H., and M.I. contributed equally to this work. elements (3). Interactions of the AF-1 and AF-2 domains with 2To whom correspondence may be addressed: E-mail: [email protected] or roeder@ various transcription coactivators are required for this process rockefeller.edu. – (4 6). Among these diverse coactivators, Mediator, a large 3Present address: Laboratory of Hematology, Kobe University Graduate school of Health (∼1.6 MDa) protein complex composed of at least 25–30 distinct Sciences, Kobe 654-0142, Japan subunits, has emerged as the main bridge for direct communica- This article contains supporting information online at www.pnas.org/cgi/content/full/ tion between transcriptional activators and RNA polymerase II 1001814107/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1001814107 PNAS Early Edition ∣ 1of6 Downloaded by guest on September 26, 2021 LxxLL motifs in vivo. Toward this end, we have generated MED1 impaired in Med1KI∕KI mice relative to wild-type mice. Similar LxxLL motif-mutant knockin mice and, surprisingly, found that defects were observed throughout pubertal mammary gland these mice are apparently fertile and grossly normal. However, development at different ages (Fig. S2). they do exhibit profound defects in virgin mammary gland devel- To determine if the mammary gland defects observed in KI∕KI opment. Consistent with this observation, we observed significant Med1 mice resulted from disrupted cell proliferation, we impairments both in ERα-dependent gene expression in mam- performed BrdU incorporation assays (25). Seven- to eight- KI∕KI mary epithelial cells and in estrogen-stimulated mammary ductal week-old wild-type and Med1 age-matched female mice growth. Moreover, we found that MED1 is differentially ex- were injected intraperitoneally with BrdU 2 h prior to sacrifice. pressed in mammary epithelial cells and plays a role in luminal Mammary glands were harvested, fixed, and then subjected to lineage determination. BrdU staining. Ten random areas of 100 cells in each sample were selected and counted to estimate the percentage of total epithe- Results lial cells that were BrdU-positive (Fig. 1 D and E). As expected, Med1KI∕KI Mice Exhibit Profound Defects in Pubertal Mammary Gland about 20% of mammary epithelial cells stained positive for BrdU Development. in wild-type mice. In contrast, there were about 4 times fewer To study the role of the MED1 LxxLL motifs in a KI∕KI physiological context, we generated MED1 LxxLL motif-mutant BrdU-positive mammary epithelial cells in the Med1 mice. 1KI∕KI These data support the idea that the observed mammary gland knockin mice (Med ). The point mutations that were intro- KI∕KI duced result in conversion of both MED1 LxxLL motifs to LxxAA defects in Med1 mice are caused, at least in part, by motifs (Fig. 1A and Fig. S1), which previously was shown to decreased cell proliferation. disrupt strong Mediator-nuclear receptor interactions in vitro KI∕KI α (14, 15). These mutations had no effect on the expression level Med1 Mice Show Impaired ER Target Gene Expression in of the MED1 protein (Fig. S1). Surprisingly, in contrast to Mammary Epithelial Cells. Estrogen is the dominant hormone pro- the embryonic lethality of a total MED1 knockout (24), moting mammary epithelial cell proliferation at the stage of Med1KI∕KI mice were viable, fertile, and grossly normal. How- mammary gland development that we studied. Thus, we reasoned ever, they did exhibit profound defects in mammary gland devel- that the mutations in the MED1 LxxLL motifs exerted their ef- opment. In these studies, mammary glands of 8-week-old fects by disrupting the estrogen signaling pathway, either by in- KI∕KI fluencing the production of estrogen or by directly affecting Med1 and wild-type virgin mice were isolated, fixed in Car- ERα-mediated transcription. To discriminate between these noy’s solution, and then stained with Carmine. As shown morpho- possibilities, we first examined the blood estrogen levels of 8- logically in Fig.
Load more

Recommended publications
  • Cross-Talk Between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells
    Published OnlineFirst September 10, 2012; DOI: 10.1158/0008-5472.CAN-12-1305 Cancer Tumor and Stem Cell Biology Research Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells Jiajun Cui1, Katherine Germer1, Tianying Wu2, Jiang Wang3, Jia Luo5, Shao-chun Wang1, Qianben Wang4, and Xiaoting Zhang1 Abstract Despite the fact that most breast cancer patients have estrogen receptor (ER) a-positive tumors, up to 50% of the patients are or soon develop resistance to endocrine therapy. It is recognized that HER2 activation is one of the major mechanisms contributing to endocrine resistance. In this study, we report that the ER coactivator MED1 is a novel cross-talk point for the HER2 and ERa pathways. Tissue microarray analysis of human breast cancers revealed that MED1 expression positively correlates most strongly with HER2 status of the tumors. MED1 was highly phosphorylated, in a HER2-dependent manner, at the site known to be critical for its activation. Importantly, RNAi-mediated attenuation of MED1 sensitized HER2-overexpressing cells to tamoxifen treatment. MED1 and its phosphorylated form, but not the corepressors N-CoR and SMRT, were recruited to the ERa target gene promoter by tamoxifen in HER2-overexpressing cells. Significantly, MED1 attenuation or mutation of MED1 phosphorylation sites was sufficient to restore the promoter recruitment of N-CoR and SMRT. Notably, we found that MED1 is required for the expression of not only traditional E2-ERa target genes but also the newly described EGF-ERa target genes. Our results additionally indicated that MED1 is recruited to the HER2 gene and required for its expression.
    [Show full text]
  • PPM1G Promotes the Progression of Hepatocellular Carcinoma Via
    www.nature.com/cddis ARTICLE OPEN PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3 ✉ ✉ Dawei Chen1, Zhenguo Zhao1, Lu Chen1, Qinghua Li1, Jixue Zou 2 and Shuanghai Liu 1 © The Author(s) 2021 Emerging evidence has demonstrated that alternative splicing has a vital role in regulating protein function, but how alternative splicing factors can be regulated remains unclear. We showed that the PPM1G, a protein phosphatase, regulated the phosphorylation of SRSF3 in hepatocellular carcinoma (HCC) and contributed to the proliferation, invasion, and metastasis of HCC. PPM1G was highly expressed in HCC tissues compared to adjacent normal tissues, and higher levels of PPM1G were observed in adverse staged HCCs. The higher levels of PPM1G were highly correlated with poor prognosis, which was further validated in the TCGA cohort. The knockdown of PPM1G inhibited the cell growth and invasion of HCC cell lines. Further studies showed that the knockdown of PPM1G inhibited tumor growth in vivo. The mechanistic analysis showed that the PPM1G interacted with proteins related to alternative splicing, including SRSF3. Overexpression of PPM1G promoted the dephosphorylation of SRSF3 and changed the alternative splicing patterns of genes related to the cell cycle, the transcriptional regulation in HCC cells. In addition, we also demonstrated that the promoter of PPM1G was activated by multiple transcription factors and co-activators, including MYC/MAX and EP300, MED1, and ELF1. Our study highlighted the essential role of PPM1G in HCC and shed new light on unveiling the regulation of alternative splicing in malignant transformation. Cell Death and Disease (2021) 12:722 ; https://doi.org/10.1038/s41419-021-04013-y INTRODUCTION The AR-V7 is specifically highly expressed in patients with relapse Hepatocellular carcinoma (HCC) is one of the most aggressive and drug resistance after targeted therapy.
    [Show full text]
  • Ectopic Protein Interactions Within BRD4–Chromatin Complexes Drive Oncogenic Megadomain Formation in NUT Midline Carcinoma
    Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma Artyom A. Alekseyenkoa,b,1, Erica M. Walshc,1, Barry M. Zeea,b, Tibor Pakozdid, Peter Hsic, Madeleine E. Lemieuxe, Paola Dal Cinc, Tan A. Incef,g,h,i, Peter V. Kharchenkod,j, Mitzi I. Kurodaa,b,2, and Christopher A. Frenchc,2 aDivision of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; bDepartment of Genetics, Harvard Medical School, Boston, MA 02115; cDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; dDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115; eBioinfo, Plantagenet, ON, Canada K0B 1L0; fDepartment of Pathology, University of Miami Miller School of Medicine, Miami, FL 33136; gBraman Family Breast Cancer Institute, University of Miami Miller School of Medicine, Miami, FL 33136; hInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136; iSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136; and jHarvard Stem Cell Institute, Cambridge, MA 02138 Contributed by Mitzi I. Kuroda, April 6, 2017 (sent for review February 7, 2017; reviewed by Sharon Y. R. Dent and Jerry L. Workman) To investigate the mechanism that drives dramatic mistargeting of and, in the case of MYC, leads to differentiation in culture (2, 3). active chromatin in NUT midline carcinoma (NMC), we have Similarly, small-molecule BET inhibitors such as JQ1, which identified protein interactions unique to the BRD4–NUT fusion disengage BRD4–NUT from chromatin, diminish megadomain- oncoprotein compared with wild-type BRD4.
    [Show full text]
  • Gene Network Analysis of PPAR-Γ: a Bioinformatics Approach Using STRING
    World Academy of Science, Engineering and Technology International Journal of Bioengineering and Life Sciences Vol:1, No:1, 2007 Gene Network Analysis of PPAR-γ: A Bioinformatics Approach Using STRING S. Bag, S. Ramaiah, P. Anitha, K. M. Kumar, P. Lavanya, V. Sivasakhthi, A. Anbarasu receptors (NRs) that are ligand-dependent transcription factors Abstract—Gene networks present a graphical view at the level and are important regulators of lipid storage and metabolism of gene activities and genetic functions and help us to understand [6]. PPAR-γ has been implicated in diseases associated with complex interactions in a meaningful manner. In the present study, dysregulation of lipid levels, such as obesity, cardiovascular we have analyzed the gene interaction of PPAR-γ (peroxisome disease, and type 2 diabetes [6]. It has many pleiotropic proliferator-activated receptor gamma) by search tool for retrieval of interacting genes. We find PPAR-γ is highly networked by genetic functions; it plays a crucial role in the expression of key genes interactions with 10 genes: RXRA (retinoid X receptor, alpha), involved in adipogenesis [7], carbohydrates metabolism [7], PPARGC1A (peroxisome proliferator-activated receptor gamma, inflammation [7], and cancer [7] and hence can form a coactivator 1 alpha), NCOA1 (nuclear receptor coactivator 1), complex network with different disease causing genes. Even NR0B2 (nuclear receptor subfamily 0, group B, member 2), HDAC3 though there are many reports [7] on the association of PPAR- (histone deacetylase 3), MED1 (mediator complex subunit 1), INS γ with other disorders, there are no reports on the gene (insulin), NCOR2 (nuclear receptor co-repressor 2), PAX8 (paired box 8), ADIPOQ (adiponectin) and it augurs well for the fact that network analysis of PPAR-γ using bioinformatics tools.
    [Show full text]
  • PRDM16 Binds MED1 and Controls Chromatin Architecture to Determine a Brown Fat Transcriptional Program
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press PRDM16 binds MED1 and controls chromatin architecture to determine a brown fat transcriptional program Matthew J. Harms,1,2,4 Hee-Woong Lim,1,3,4 Yugong Ho,3 Suzanne N. Shapira,1,2 Jeff Ishibashi,1,2 Sona Rajakumari,1,2 David J. Steger,1 Mitchell A. Lazar,1 Kyoung-Jae Won,1,3 and Patrick Seale1,2 1Institute for Diabetes, Obesity, and Metabolism, 2Department of Cell and Developmental Biology, 3Genetics Department, Smilow Center for Translational Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA PR (PRD1–BF1–RIZ1 homologous) domain-containing 16 (PRDM16) drives a brown fat differentiation program, but the mechanisms by which PRDM16 activates brown fat-selective genes have been unclear. Through chromatin immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) analyses in brown adipose tissue (BAT), we reveal that PRDM16 binding is highly enriched at a broad set of brown fat-selective genes. Importantly, we found that PRDM16 physically binds to MED1, a component of the Mediator complex, and recruits it to superenhancers at brown fat-selective genes. PRDM16 deficiency in BAT reduces MED1 binding at PRDM16 target sites and causes a fundamental change in chromatin architecture at key brown fat-selective genes. Together, these data indicate that PRDM16 controls chromatin architecture and superenhancer activity in BAT. [Keywords: PRDM16; PRDM3; MED1; Mediator; brown adipose tissue; UCP1] Supplemental material is available for this article. Received September 17, 2014; revised version accepted December 10, 2014. Obesity is a leading cause of preventable death in the United required for beige fat differentiation and the maintenance of States due to its link to many diseases, including type 2 brown adipose tissue (BAT) fate in adult mice (Cohen diabetes, cardiovascular disease, stroke, and certain cancers et al.
    [Show full text]
  • Transcriptional and Epigenetic Control of Brown and Beige Adipose Cell Fate and Function
    REVIEWS Transcriptional and epigenetic control of brown and beige adipose cell fate and function Takeshi Inagaki1,2, Juro Sakai1,2 and Shingo Kajimura3 Abstract | White adipocytes store excess energy in the form of triglycerides, whereas brown and beige adipocytes dissipate energy in the form of heat. This thermogenic function relies on the activation of brown and beige adipocyte-specific gene programmes that are coordinately regulated by adipose-selective chromatin architectures and by a set of unique transcriptional and epigenetic regulators. A number of transcriptional and epigenetic regulators are also required for promoting beige adipocyte biogenesis in response to various environmental stimuli. A better understanding of the molecular mechanisms governing the generation and function of brown and beige adipocytes is necessary to allow us to control adipose cell fate and stimulate thermogenesis. This may provide a therapeutic approach for the treatment of obesity and obesity-associated diseases, such as type 2 diabetes. Interscapular BAT Adipose tissue has a central role in whole-body energy subjects who had previously lacked detectable BAT Brown adipose tissue (BAT) is a homeostasis. White adipose tissue (WAT) is the major depots before cold exposure, presumably owing to the specialized organ that adipose organ in mammals. It represents 10% or more emergence of new thermogenic adipocytes. This, then, produces heat. BAT is localized of the body weight of healthy adult humans and is leads to an increase in non-shivering thermogenesis in the interscapular and 6–9 perirenal regions of rodents specialized for the storage of excess energy. Humans and/or an improvement in insulin sensitivity . These and infants.
    [Show full text]
  • Antibodies for Epigenetics and Gene Regulation Enabling Epigenetics Research
    antibodies for epigenetics and gene regulation Enabling Epigenetics Research 3 Chromatin Modifiers DNA Methylation Histones Transcription Regulation Highly Characterized Antibodies for Epigenetics and Gene Regulation At Active Motif, we are committed to providing the highest- polyclonal and AbFlex® recombinant antibodies are quality antibodies for studying epigenetics in the context validated for the applications you need – chromatin of histone and DNA modifications. Our antibodies are immunoprecipitation (ChIP), ChIP-Seq, Western blot, and manufactured in-house, and undergo rigorous development Immunofluorescence. and validation procedures to ensure their quality and To browse our complete list of antibodies and application performance. Our extensive, novel portfolio of monoclonal, data, please visit www.activemotif.com/abs. AbFlex® Recombinant Antibodies uniquely designed for multiple labeling methods AbFlex® antibodies are recombinant antibodies (rAbs) purification systems, and that have been generated using defined DNA sequences an avidin tag sequence to produce highly specific, reproducible antibodies. The for enzymatic biotin unique advantages of the AbFlex® antibody are its flexible conjugation using the biotin labeling and purification options. Each AbFlex® antibody ligase, BirA. contains a Sortase recognition motif (LPXTG) to covalently add fluorophores, enzymatic substrates (e.g., HRP), AbFlex is available for a peptides, DNA, drugs, or other labels to the antibody in range of Histone Markers, a directed and reproducible manner.
    [Show full text]
  • Transcriptional Regulation of Autophagy Genes Via Stage
    Version October 4, 2019 submitted to Cells S1 of S23 Supplementary Materials: Transcriptional regulation of autophagy genes via stage-specific activation of CEBPB and PPARG during adipogenesis: a systematic study using public gene expression and transcription factor binding datasets Mahmoud Ahmed , Trang Huyen Lai , Jin Seok Hwang , Sahib Zada , Trang Minh Pham and Deok Ryong Kim *, 1 List of Tables 2 S1 Percent of gene expression variance explained by the stage of differentiation.......2 3 S2 Differential expression of gene markers............................3 4 S3 Autophagy and lipid metabolism gene ontology terms enrichment in differentiating 5 adipocytes.............................................4 6 S4 Significant peaks of adipogenic factors on autophagy genes.................5 7 S5 Significant peaks of adipogenic factors on autophagy transcription factor genes.....6 8 S6 Autophagy and lipid metabolism gene ontology terms enrichment in Cebpb and 9 Pparg-knockdown differentiating adipocytes.........................7 10 S7 Peaks of adipogenic factors on adipogenic transcription factor genes...........8 11 S8 Datasets of RNA and ChIP Seq.................................9 12 S9 ChIP antibodies for transcription factors, co-factors and histone markers.......... 10 13 S10 Datasets of ChIP Seq in different tissues............................ 11 14 S11 Datasets of RNA Seq and microarrays of adipocytes with Cebpb or Pparg-knockdown.. 12 15 List of Figures 16 S1 Differential gene expression in early and late differentiating adipocytes.......... 13 17 S2 Differential peak binding of adipogenic transcription factors on autophagy genes.... 14 18 S3 Gene markers of differentiation, lipogenesis and autophagy................. 15 19 S4 Co-expression of adipogenic transcription factors genes with autophagy genes..... 16 20 S5 Tissue specific binding of adipogenic transcription factors................
    [Show full text]
  • Enhancers and Super-Enhancers Have an Equivalent Regulatory Role in Embryonic Stem Cells Through Regulation of Single Or Multiple Genes
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes Authors: Sakthi D Moorthy*1, Scott Davidson*1, Virlana M Shchuka1, Gurdeep Singh1, Nakisa Malek- Gilani1, Lida Langroudi1, Alexandre Martchenko1, Vincent So1, Neil N Macpherson1, and Jennifer A Mitchell1,2. * These authors contributed equally 1) Department of Cell and Systems Biology, University of Toronto, Toronto, ON, M5S 3G5, Canada. 2) Centre for the Analysis of Genome Evolution and Function, University of Toronto, Toronto, ON, M5S 3G5, Canada. Contact: Jennifer A Mitchell, Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, Ontario M5S 3G5, Canada. Phone: (416)978-6711, Fax: (416)978-8532, Email: [email protected]. Running Title: Enhancer and super-enhancer equivalence Keywords: Transcription, Enhancer Elements, Super-enhancers, Embryonic Stem Cells, Gene Expression Regulation. 1 Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Transcriptional enhancers are critical for maintaining cell type-specific gene expression and driving cell fate changes during development. Highly transcribed genes are often associated with a cluster of individual enhancers such as those found in locus control regions. Recently these have been termed stretch enhancers or super-enhancers, which have been predicted to regulate critical cell identity genes. We employed a CRISPR/Cas9-mediated deletion approach to study the function of several enhancer clusters (ECs) and isolated enhancers in mouse embryonic stem (ES) cells. Our results reveal that the effect of deleting ECs, also classified as ES cell super-enhancers, is highly variable, resulting in target gene expression reductions ranging from 12% to as much as 92%.
    [Show full text]
  • Interplay Between Cofactors and Transcription Factors in Hematopoiesis and Hematological Malignancies
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies Zi Wang 1,2, Pan Wang2, Yanan Li2, Hongling Peng1, Yu Zhu2, Narla Mohandas3 and Jing Liu2 Hematopoiesis requires finely tuned regulation of gene expression at each stage of development. The regulation of gene transcription involves not only individual transcription factors (TFs) but also transcription complexes (TCs) composed of transcription factor(s) and multisubunit cofactors. In their normal compositions, TCs orchestrate lineage-specific patterns of gene expression and ensure the production of the correct proportions of individual cell lineages during hematopoiesis. The integration of posttranslational and conformational modifications in the chromatin landscape, nucleosomes, histones and interacting components via the cofactor–TF interplay is critical to optimal TF activity. Mutations or translocations of cofactor genes are expected to alter cofactor–TF interactions, which may be causative for the pathogenesis of various hematologic disorders. Blocking TF oncogenic activity in hematologic disorders through targeting cofactors in aberrant complexes has been an exciting therapeutic strategy. In this review, we summarize the current knowledge regarding the models and functions of cofactor–TF interplay in physiological hematopoiesis and highlight their implications in the etiology of hematological malignancies. This review presents a deep insight into the physiological and pathological implications of transcription machinery in the blood system. Signal Transduction and Targeted Therapy (2021) ;6:24 https://doi.org/10.1038/s41392-020-00422-1 1234567890();,: INTRODUCTION by their ATPase subunits into four major families, including the Hematopoiesisisacomplexhierarchicaldifferentiationprocessthat SWI/SNF, ISWI, Mi-2/NuRD, and INO80/SWR1 families.
    [Show full text]
  • Biochemistry. in the Article “The Med1 Subunit of the Yeast Mediator Complex Is Involved in Both Transcriptional Activation An
    3330 Corrections Proc. Natl. Acad. Sci. USA 96 (1999) Biochemistry. In the article “The Med1 subunit of the yeast Neurobiology. In the article “Caspase-1 is activated in neural mediator complex is involved in both transcriptional activation cells and tissue with amyotrophic lateral sclerosis-associated and repression” by Darius Balciunas, Cecilia Ga¨lman,Hans mutations in copper-zinc superoxide dismutase” by Piera Ronne, and Stefan Bjo¨rklund, which appeared in number 2, Pasinelli, David R. Borchelt, Megan K. Houseweart, Don W. January 19, 1999, of Proc. Natl. Acad. Sci. USA (96, 376–381), Cleveland, and Robert H. Brown, Jr., which appeared in due to a printer’s error, the affiliation symbols were incorrect. number 26, December 22, 1998, of Proc. Natl. Acad. Sci. USA The correct author line, affiliation line, and address footnotes (95, 15763–15768), the following corrections should be noted. appear below. An erroneous version of Fig. 6 was published. The lane indicated as G41D represents lumbo-sacral spinal cord extract from G85R transgenic mice. In Fig. 7a, cell viability is ex- DARIUS BALCIUNAS*†,CECILIA GALMAN¨ ‡§, pressed as % of untreated cells and not as % of viability. HANS RONNE*†, AND STEFAN BJORKLUND¨ ‡¶ ‡Department of Medical Biochemistry and Biophysics, Umeå University, Physiology. In the article “Inositol 1,4,5-tris-phosphate acti- S-901 87 Umeå, Sweden; and *Department of Medical Biochemistry and vation of inositol tris-phosphate receptor Ca21 channel by Microbiology, Uppsala University Biomedical Center, Box 582, 751 23 21 Uppsala, Sweden ligand tuning of Ca inhibition” by Don-On Daniel Mak, Sean McBride, and J. Kevin Foskett, which appeared in number 26, December 22, 1998, of Proc.
    [Show full text]
  • Role of Estrogen Receptor Coregulators in Endocrine Resistant Breast Cancer Kristin A
    Exploration of Targeted Anti-tumor Therapy Open Access Review Role of estrogen receptor coregulators in endocrine resistant breast cancer Kristin A. Altwegg1,2 , Ratna K. Vadlamudi1,2* 1Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA 2Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA *Correspondence: Ratna K. Vadlamudi, Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA. [email protected] Academic Editor: Simon Langdon, University of Edinburgh, UK Received: May 27, 2021 Accepted: July 2, 2021 Published: August 30, 2021 Cite this article: Altwegg KA, Vadlamudi RK. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor Target Antitumor Ther. 2021;2:385-400. https://doi.org/10.37349/etat.2021.00052 Abstract Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70-80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid hormone estrogen [17β-estradiol (E2)] plays a vital role both in the initiation and progression of BC. The E2-ERα mediated actions involve genomic signaling and non-genomic signaling. The specificity and magnitude of ERα signaling are mediated by interactions coregulators are common during BC progression and they enhance ligand-dependent and ligand-independent between ERα and several coregulator proteins called coactivators or corepressors. Alterations in the levels of proteins function as scaffolding proteins and some have intrinsic or associated enzymatic activities, thus the ERα signaling which drives BC growth, progression, and endocrine therapy resistance.
    [Show full text]